Pharmaceutical Executive Editorial Staff

Incidence rates have grown for leptomeningeal metastasis, a rapidly progressing and fatal complication of several cancers.

The newly approved Alinity m high risk human papillomavirus (HPV) assay is indicated to detect HPV and for use in routine cervical cancer screening per professional medical guidelines.

Phathom Pharmaceuticals announced that it anticipates vonoprazan (Voquenza) to be commercially available by December 2023.

The branded form of secukinumab is currently the only FDA-approved fully human biologic that directly inhibits interleukin-17A.

Abatacept is indicated across multiple inflammatory conditions, including for the treatment of adult patients with moderately to severely active rheumatoid arthritis, pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis, and active juvenile psoriatic arthritis.

The FDA granted Wezlana with interchangeable designation after clinical trials found no clinically significant differences in safety and efficacy for the indicated conditions across multiple inflammatory diseases.

The Alliance for mRNA Medicines is the first and only scientific and policy organization singularly focused on advancing and advocating for global mRNA innovation.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

Hernandez details how the non-profit organization advocates for improved access to care at the community, state, and federal levels, and amplifies education and awareness efforts within its social media communities.

Building on Organon’s prior FP2030 commitment, the company announces $30 million in new funding to fuel global action and community-driven solutions needed by the 121 million women and girls who experience unplanned pregnancies each year.

Nelarabine Injection ensures access to a lifesaving treatment, particularly for children, that historically has been in shortage.

Standard Media Index's latest data suggests that 2022 may have been a tipping point in the transition to digital pharma advertising.

Pharmaceutical companies are increasingly using radio advertising, both traditional and digital.

Survey: HCPs Rank Corporate Reputation as Leading Factor After Drug Efficacy and Safety

Enterprise generative AI focused on life sciences to bring life-saving drugs to market faster.

The companies have entered a partnership agreement to develop new digital solutions for the objective assessment and management of pain associated with endometriosis, which they have been jointly developing since July 2020.

The drug is Xspray Pharma's first innovative cancer therapy and is set to launch later in 2023.

Blueprint Medicines Corporation will regain global commercialization and development rights to Gavreto (pralsetinib).

The therapy to treat a type of inherited bleeding disorder known as hemophilia A is expected to launch in the United States in April.

Wall Street Journal reports psychedelic-therapy industry gets a reality trip as investors focus on treatments costing less time and money

Bausch + Lomb has launched a social media campaign called "What Sight Inspires You" to raise awareness of age-related macular degeneration.

Sermo and LiveWorld survey of 50+ pharma marketers and 200+ physicians finds that social media plays a major role in influencing perceptions of medications, prescribing Habits, ongoing medical education and professional networking.

The capabilities will support life sciences organizations with a variety of use cases, including health care provider (HCP) interactions, HCP education, and patient education.

Pharm Exec spoke with Skalicky about new ways that life sciences companies are engaging with outsourcing.

A new study shows that a growing number of younger generations are turning to social media platforms such as TikTok and Instagram influencers for health advice.

Move enables FINN to address pressing health priorities in developed and developing nations and expands Hyderus global service capabilities and client offerings and Hyderus co-founders Mark Chataway and Christopher Nial join FINN global health leaders team.

Takeda's partnership with Novavax to manufacture 150 million doses of COVID-19 vaccine has been heavily impacted.

AstraZeneca is forecasting growth in 2023 and beyond, relying on its expanding line of cancer, metabolic, and rare disease drugs to offset declining COVID product sales.

Pharm Exec spoke with the senior vice president and vice president and therapeutic area head of global medical, inflammation & representation in clinical research at Amgen about how important health equity is to the entire industry.

BMS launched a new direct-to-consumer (DTC) campaign for SOTYKTU™ (deucravacitinib) for the plaque psoriasis community.